Sales of implants are set to fall sharply as non-urgent procedures are deferred.
As Smiths Group delays its split partly so it can focus on ventilator production, the US FDA grants emergency authorisation to other breathing devices to treat Covid-19.
Clinical results this year from companies including Roche, Biogen and Sanofi should show whether new drug classes can arrest the development of Parkinson’s disease.
Tirzepatide’s clinical programme is set to double in size when a huge head-to-head outcome study gets under way. Costs will balloon too.
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
The orthopaedics sector has seen several sizeable mergers over the past decade. Might it see more?
The company plans to make the most of its head start with the Graves’ disease project teprotumumab, which is forecast to become its biggest product.
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
Competition is looming from Novartis and Roche but the latest results from Spinraza show that Biogen still has a strong case to make for the SMA therapy.